| Heterogeneity of tumor and immune cell PD-L1 expression and lymphocyte counts in surgical NSCLC samples D Casadevall, S Clavé, Á Taus, M Hardy-Werbin, P Rocha, M Lorenzo, ... Clinical lung cancer 18 (6), 682-691. e5, 2017 | 87 | 2017 |
| MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC) D Casadevall, J Gimeno, S Clavé, Á Taus, L Pijuan, M Arumí, M Lorenzo, ... Oncotarget 6 (18), 16215, 2015 | 62 | 2015 |
| Clinical impact of presurgery circulating tumor DNA after total neoadjuvant treatment in locally advanced rectal cancer: a biomarker study from the GEMCAD 1402 trial J Vidal, D Casadevall, B Bellosillo, C Pericay, R Garcia-Carbonero, ... Clinical Cancer Research 27 (10), 2890-2898, 2021 | 54 | 2021 |
| Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women T O’Meara, A Safonov, D Casadevall, T Qing, A Silber, B Killelea, C Hatzis, ... Breast cancer research and treatment 175, 247-259, 2019 | 54 | 2019 |
| Quantification of specific antibodies against SARS-CoV-2 in breast milk of lactating women vaccinated with an mRNA vaccine E Esteve-Palau, A Gonzalez-Cuevas, ME Guerrero, C Garcia-Terol, ... JAMA network open 4 (8), e2120575-e2120575, 2021 | 46 | 2021 |
| CD274 (PDL1) and JAK2 genomic amplifications in pulmonary squamous‐cell and adenocarcinoma patients S Clavé, L Pijuan, D Casadevall, Á Taus, J Gimeno, S Hernández‐Llodrà, ... Histopathology 72 (2), 259-269, 2018 | 32 | 2018 |
| LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer I Pérez-Núñez, C Rozalén, JÁ Palomeque, I Sangrador, M Dalmau, ... Nature cancer 3 (3), 355-370, 2022 | 26 | 2022 |
| The prognostic role of epigenetic dysregulation in bladder cancer: A systematic review D Casadevall, AY Kilian, J Bellmunt Cancer Treatment Reviews 61, 82-93, 2017 | 24 | 2017 |
| Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion A Lluch, AM González-Angulo, D Casadevall, AK Eterovic, EM de Dueñas, ... European Journal of Cancer 120, 54-64, 2019 | 23 | 2019 |
| Preclinical and clinical characterization of fibroblast-derived neuregulin-1 on trastuzumab and pertuzumab activity in HER2-positive breast cancer C Guardia, G Bianchini, O Arpí-LLucià, S Menendez, D Casadevall, ... Clinical Cancer Research 27 (18), 5096-5108, 2021 | 13 | 2021 |
| Liquid biopsy detects early molecular response and predicts benefit to first-line chemotherapy plus cetuximab in metastatic colorectal cancer: PLATFORM-B study J Vidal, MC Fernández-Rodríguez, D Casadevall, P García-Alfonso, ... Clinical Cancer Research 29 (2), 379-388, 2023 | 11 | 2023 |
| Circulating tumor cells: applications for early breast cancer T Martos, D Casadevall, J Albanell Circulating tumor cells in breast cancer metastatic disease, 135-146, 2020 | 11 | 2020 |
| Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report D Casadevall, J Vidal, F Gallardo, F Zuccarino, M Arumí-Uría, A Dalmases, ... Journal of Medical Case Reports 10, 1-5, 2016 | 9 | 2016 |
| mTOR inhibition and T-DM1 in HER2-positive breast cancer D Casadevall, A Hernández-Prat, S García-Alonso, O Arpí-Llucià, ... Molecular Cancer Research 20 (7), 1108-1121, 2022 | 8 | 2022 |
| Comparison of different methods for defining hyperprogressive disease in NSCLC P Rocha, D Ramal, E Ripoll, L Moliner, A Corbera, M Hardy-Werbin, ... JTO Clinical and Research Reports 2 (1), 100115, 2021 | 7 | 2021 |
| Predicting recurrence of venous thromboembolism in anticoagulated cancer patients using real-world data and machine learning. AJ Muñoz Martín, S Huerga Domínguez, JC Souto, J Rogado Revuelta, ... Journal of Clinical Oncology 40 (16_suppl), e18742-e18742, 2022 | 6 | 2022 |
| Quantification and progress over time of specific antibodies against severe acute respiratory syndrome coronavirus 2 in breast milk of lactating women vaccinated with BNT162b2 … E Esteve-Palau, A Gonzalez-Cuevas, ME Guerrero, C Garcia-Terol, ... Open Forum Infectious Diseases 9 (6), ofac239, 2022 | 5 | 2022 |
| Genomic and immune profiling of a patient with triple-negative breast cancer that progressed during neoadjuvant chemotherapy plus PD-L1 blockade D Casadevall, X Li, RL Powles, VB Wali, N Buza, V Pelekanou, A Dhawan, ... JCO Precision Oncology 3, 2019 | 5 | 2019 |
| Comprehensive analysis of metabolic isozyme targets in cancer M Marczyk, V Gunasekharan, D Casadevall, T Qing, J Foldi, R Sehgal, ... Cancer research 82 (9), 1698-1711, 2022 | 3 | 2022 |
| Is there a role for epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor wild-type non-small cell lung cancer? E Arriola, Á Taus, D Casadevall World Journal of Clinical Oncology 6 (4), 45, 2015 | 3 | 2015 |
